Pacifico Yokohama, Japan      October 10 (Wed.) – 12 (Fri.), 2018

To Pre-register for the seminars, please complete the visitor registration first.
*If you already completed above, you can proceed your seminar registration from your visitor account.
✔ Register Now → Account Login

Organizer

Oct.10(Wed.)      10  :  00  ~  11  :  30

F203-206
【K-1】 Keynote Lecture
Pre-Registration required Simultaneous interpretation

Keynote Lecture

The Japanese Government’s Strategy and the Sumitomo Chemical Group’s Initiatives in the Field of Biotechnology

Mr. Masakazu Tokura

Representative Director & President
Sumitomo Chemical Company, Limited / Member, Council for Science, Technology and Innovation

In Japanese

The Future of Drug Discovery Innovation

Mr. George Nakayama

President
Japan Pharmaceutical Manufacturers Association

In Japanese

Outlook on Super Aged Society
 - Perspectives on social security system reform -

Mr. Yoshihide Esaki

Deputy Director-General for Healthcare and Medical Policy,
Ministry of Economy, Trade and industry Commerce and Service Policy Group, Ministry of Health, Labor and Welfare Healthcare and Medical Policy Bureau, Healthcare and Medical Policy office Cabinet Secretariat Government of Japan

In Japanese

Luncheon

Oct.10(Wed.)      12  :  00  ~  13  :  00

F201
【L-1】 Bayer Yakuhin, Ltd.
Pre-Registration required Full Simultaneous interpretation

Open Innovation Strategy at Bayer

At Bayer, since the establishment of Open Innovation Center in 2014, we have been seeking partners in diverse areas of drug discovery researches quite actively in Japan. As the result, we successfully formed research alliances with multiple universities and biotech companies. Moreover, in June this year, we opened a biotech venture incubator for the first time among the foreign-affiliated companies. In this seminar, we will introduce our global open innovation strategy and our local activities focusing on CoLaborator Kobe.

Coordinator

Dr. Koji Yashiro

Alliance Manager
Open Innovation Center Japan
Bayer Yakuhin, Ltd

Open Innovation@Bayer

Dr. Monika Lessl

Vice President, Head of Corporate Innovation and R&D
Bayer AG

Open Innovation Strategy in Japan

Dr. Shunichi Takahashi

Head of Open Innovation Center Japan
Bayer Yakuhin, Ltd.

In Japanese

Organizer

Oct.10(Wed.)      13  :  00  ~  14  :  30

F205-206
【O-1】 Life-Innovation Forum
Admission Fee required Pre-Registration required Simultaneous interpretation

Life Innovation Forum - Era of Integrated Healthcare -

Practical and sustainable system, which link clinics to advanced medicine, is needed for integrated healthcare. The application of digital technology also should be considered. In this seminar, we are introducing challenges of Europe and Japan, and are discussing what is needed for innovation.

Coordinator

Dr. Tatsumi Yamazaki

Chairman of the Steering Committee
Japan Bioindustry Association

The Global Innovation model: Current Challenges and Opportunities

Mr. Joseph Damond

Executive Vice President, International Affairs
Biotechnology Innovation Organization

The Connected Health Cities method: driving innovation in areas of need

Dr. Amanda Lamb

COO
Connected Health Cities

Transforming Healthcare - A Singapore Perspective

Dr. Benjamin Seet

Executive Director
Biomedical Research Council
A*STAR

Mission of AMED:Global data sharing

Dr. Makoto Suematsu

President
Japan Agency for Medical Research and Development

In Japanese

Panel discussion


Oct.10(Wed.)      13  :  15  ~  14  :  15

F202
【S-2】 NITTO PHARMACEUTICAL INDUSTRIES, LTD
Pre-Registration required Full Simultaneous interpretation

''Postbiotics'' for health -Analysis and application of functional gut microbial metabolites-

Our intestine is inhabited by a large diverse microbiota. It is important to reveal what kind metabolites are produced by gut microorganisms and understand the health effects of the metabolites. The new analytical method of gut microbial lipid metabolites and application of newly found metabolites to health promotion will be introduced. This information expand our knowledge of the molecular basis on the mutual relationship between the host and the gut microbiota. The discussion could open a new concept ''postbiotics to benefit everybody''.

Coordinator

Prof. Jun Ogawa

Professor
Division of Applied Life Sciences
Graduate Schools Agriculture, Kyoto University

Health promoting novel gut microbial metabolisms, its finding and application

Prof. Jun Ogawa

Professor
Division of Applied Life Sciences
Graduate Schools Agriculture, Kyoto University

In Japanese

Advanced lipidomics strategy to identify bioactive lipids

Prof. Makoto Arita

Professor, Division of Physiological Chemisty and Metabolism, Keio University Faculty of Phamacy / Team Leader, Laboratory for Metabolomics , RIKEN Center for Integrative Medical Sciences

In Japanese

Development of functional fatty acids using lactic acid bacteria

Dr. Yasunori Yonejima

Section manager
R & D Division, Postbiotics Research Center with Microorganisms
Nitto Pharmaceutical Industries, LTD.

In Japanese

Organizer

Oct.10(Wed.)      13  :  30  ~  15  :  00

F201
【O-2】 Evolution of gene therapy toward commercialization
Admission Fee required Pre-Registration required Full Simultaneous interpretation

Evolution of gene therapy toward commercialization

Coordinator

Mr. Naoki Okamura

Chief Strategy Officer
Astellas Pharma Inc.

Introduction

Mr. Naoki Okamura

Chief Strategy Officer
Astellas Pharma Inc.

REGENXBIO: AAV gene therapy for wet AMD and rare diseases

Mr. Andrew Yost

Vice President
Corporate Development
REGENXBIO Inc.

CNS gene therapy: Potential and challenges

Prof. Mimoun Azzouz

Chair of Translational Neuroscience
Neuroscience
University of Sheffield

Dawn of Engineered T Cell Therapy

Mr. MASANOBU KIMURA

Director, President of Gene Medicine Business Unit
TAKARA BIO INC

Oct.10(Wed.)      15  :  30  ~  16  :  30

F201
【S-3】 Chugai Pharmaceutical Co., Ltd.
Pre-Registration required Full Simultaneous interpretation

Personalized healthcare approach by Chugai

Personalized healthcare approch by Chugai

Dr. Yasushi Ito

Excecutive Vice President
Chugai Pharmaceutical Co., Ltd.

In Japanese

Personalized Cancer Care. Delivered.

Ms. Melanie Nallicheri

Chief Business Officer & Head, Biopharma
Foundation Medicine Inc.

Organizer

Oct.11(Thu.)      10  :  00  ~  11  :  30

F201
【O-6】 Three challenging tasks for development of innovative nucleic acid drugs: selectivity, delivery and cost
Admission Fee required Pre-Registration required Full Simultaneous interpretation

Three challenging tasks for development of innovative nucleic acid drugs: selectivity, delivery and cost

In recent years, the development and launch of nucleic acid drugs has been thriving. In this session, we will review the current situation of development, clarify the issues, and discuss future trends of research and development of nucleic acid drugs. In particular, we will focus on selectivity (side effects), delivery and cost, which are the challenges in developing nucleic acid drugs.

Coordinator

Prof. Takeshi Wada

Professor
Faculty of Pharmaceutical Sciences
Tokyo University of Science

Oligonucleotide Therapeutics : The Past and the Present

Dr. Nagata Tetsuya

Research associate professor
Department of Neurology and Neurological Science
Tokyo Medical and Dental University

In Japanese

Development of a platform technology for non-toxic oligonucleotide therapeutics

Prof. Satoshi Obika

Professor
Graduate School of Pharamaceutical Sciences
Osaka University

In Japanese

FROM STEREOPURITY TO PRECISION MEDICINE: OPTIMIZING THE PROPERTIES OF ANTISENSE NUCLEIC ACID THERAPEUTICS

Dr. Naoki Iwamoto

Principal Scientist
Drug Discovery,
Wave Life Sciences

Oligo manufacturing to assist the growth of the pipeline and the commercial products

Mr. Nobuhiko Nishio

Manager
Business Management Dept. Medical Div.
Nitto Denko Corporation

In Japanese

Oct.11(Thu.)      10  :  00  ~  11  :  30

F202
【S-4】 Japan Pharmaceutical Manufacturers Association
Pre-Registration required Full

" Toward industrial application of human microbiome research through cross-border collaboration within Asia”

Human microbiome research has been recognized as the emerging research area based on many findings suggesting significant relationship between human microbiome and human health status as well as many diseases. There are still hurdles to realize application of human microbiome data to healthcare industry mainly due to lack of reliable protocols which guarantee reproducibility of data.
In addition, it is well known that the microbiome composition is significantly different in different ethnic regions. For example, composition of Japanese gut microbiome is quite unique compared to others. Therefore, promotion of industrial application of human microbiome research requires reliable databases established based upon regional and ethnic backgrounds.
In this session, we will invite a key opinion leader from the Netherlands to know how they have generated reliable database from cohort studies. We will also invite some researchers from Asian countries to grasp ongoing activities on human microbiome research in their countries. In addition, an activity of JMBC, an industry consortium to promote application of microbiome research to industry, will be presented. At the panel discussion, we will exchange ideas about how to promote industrial application of human microbiome research within Asia by leveraging cross-border collaborations.

Coordinator

Dr. Jun Terauchi

Steering Committee Chair
Japan Microbiome Consortium

Dr. Wei-Kang Chi

Distinguished Scientist
Development Center for Biotechnology, Taiwan

The Lifelines cohort study: building a 10K Metagenomics project in healthy volunteers

Mr. Bart Scheerder

Director
Biobank Knowledge and Expertise center,
University Medical Center Groningen

. Introduction of Asian Microbiome Project: Comparative gut microbiome study within and across countries

Dr. Jiro Nakayama

Associate Professor
Department of Bioscience and Biotechnology, Faculty of Agriculture,
Kyushu University

Introduction of Japan Microbiome Consortium aiming industrial application in Japan

Dr. Jun Terauchi

Steering Committee Chair
Japan Microbiome Consortium

Creation of standard platform for human microbiome measurement

Dr. Sekiguchi Yuji

Group Leader,
Advanced Biomeasurements Research Group, Biomedical Research Institute
The National Institute of Advanced Industrial Science and Technology

Introduction of Microbiome Researches and Microbiota Consortium in Taiwan

Dr. Ming-Shiang Wu

Distinguished Professor & Chairman
Department of Internal Medicine
National Taiwan university, college of medicine

Introduction of APAC DA-EWG initiative

Dr. Atsushi Hasuoka

Leader
APAC DA-EWG

Organizer

Oct.11(Thu.)      11  :  45  ~  13  :  15

F202
【O-7】 Forefront of biopharmaceutical manufacturing:Innovation of biologics production process by introducing AI
Admission Fee required Pre-Registration required Full Simultaneous interpretation

Forefront of biopharmaceutical manufacturing:Innovation of biologics production process by introducing AI

AI has already been introduced in various industrial fields. However, the introduction of AI into the development and manufacturing process of biopharmaceuticals was delayed in efforts not only in Japan but also globally. In the field of biopharmaceuticals, AI hardly penetrated due to several reasons, such as using unstable animal cells as production cells or producing by batch method.
Recently, following low molecular drugs, continuous production methods have been discussed even in biopharmaceuticals, and technological development has been actively carried out. In this process, elemental technologies such as new manufacturing materials and equipment, development of sensors for process monitoring, process analysis technology, process automation are being developed globally. Then, by introducing AI to process management, there has been a move to construct a highly productive production process by collecting all data on the process, analyzing it comprehensively, and controlling the process.
In this session, we will give lectures on relevant contents from the viewpoint of university and industry to engage in the development and manufacture of biopharmaceuticals. We will discuss how AI should be introduced in the manufacture of biopharmaceuticals, and at the same time explore why AI introduction is delayed in the development and manufacture of biopharmaceuticals in Japan.


Coordinator

Prof. Kazuhisa Uchida

Profrssor
Graduate School of Science,technology and Innovation
Kobe Univaersity

Overview

Prof. Kazuhisa Uchida

Profrssor
Graduate School of Science,technology and Innovation
Kobe Univaersity

Utilization of IT/AI technology in the production process of biologics

Prof. Michihiro Araki

Professor
Graduate school of medicine
Kyoto University

In Japanese

Automation and future applications for improvement of biopharmaceutical manufacturing through measurement, computation and control

Mr. Soichiro Shimoda

New Technology Development Center, Life Innovation Business Headquarters
Yokogawa Electric Corporation

In Japanese

Panel discussion


Luncheon

Oct.11(Thu.)      12  :  00  ~  13  :  30

F201
【L-4】 Germany Trade and Invest
Pre-Registration required Full Simultaneous interpretation

Developing shared solutions! How German-Japanese cooperation can achieve potential synergy effects.

Japan and Germany are two of the world's major pharmaceutical markets, with both countries advancing to become global heavyweights in the medical biotechnology industry. Cooperation between the two can achieve potential synergy effects that allow their respective biotech and pharmaceutical economies to become more dynamic, innovative and competitive. To support the creation of a strong German-Japanese network within the pharmaceutical and biotechnology industries, the German government initiative HEALTH MADE IN GERMANY invites German and Japanese pharmaceutical and medical biotechnology representatives to attend this luncheon seminar and panel discussion.
Major companies (e.g. Bayer and Boehringer Ingelheim), highly innovative German SMEs and start-ups as well as German representatives from biotech clusters and governmental agencies will be on hand to present available cooperation and partnership opportunities and discuss shared solutions. You are very welcomed to join HEALTH MADE IN GERMANY and the best in German medical biotech at this event.

Coordinator

Mr. Axel Lohse

Manager Medical Biotechnology and Pharmaceuticals
HEALTH MADE IN GERMANY c/o Germany Trade and Invest

Embassy of Germany in Tokyo, Japan

Dr. Shunichi Takahashi

Head of Open Innovation Center Japan
Bayer Yakuhin, Ltd.

In Japanese

Boehringer Ingelheim’s partnering strategy

Dr. Shinobu Suzuki

Head, Dept. of Research Beyond Borders and R&D Liaison
Nippon Boehringer Ingelheim

In Japanese

Dr. Marieke Mohr

Marketing / Sales Manager
BioGenes

Opportunities in Gene Therapy & Immune Oncology with Viral Vectors

Dr. Dieter Lingelbach

Managing Director, COO
SIRION BIOTECH GmbH

Charité – a tale of Japanese-German medical achievement that changed the world.

Dr. Wagner Frank

CEO/CSO
CHARITÉ RESEARCH ORGANISATION GmbH

DENARASE® - c-LEctas next level endonuclease for biopharmaceutical production

Dr. Kurz Randy

Transferassistent, BIO-NET LEIPZIG
c-LEcta

Industry-Academia collaboration

Dr. Junichi Koga

Senior Executive Officer, Head of R&D Division
Daiichi Sankyo Co., Ltd

In Japanese

Organizer

Oct.11(Thu.)      13  :  15  ~  14  :  45

F203-204
【O-8】 AI X Medicine: How can we integrate empirical expert knowledge into massive data flow by AI?
Admission Fee required Pre-Registration required Simultaneous interpretation

AI X Medicine: How can we integrate empirical expert knowledge into massive data flow by AI?

Recent advancement of measurement instrument and handling and analysis of massive data flow brings revolution of personalized and precision medicine. Traditionally, medicine relies of perception of health condition and accumulation of empirical knowledge. At most standard therapy based on limited test results was the limit. Now massive data acquisition, at molecular level (DNA, RNA protein and metabolite), at imaging level (pathology, various imaging technology) and behavior pattern level (food, exercise, sleep) is progressing.

How can we integrate traditional empirical knowledge by experts (i.e pathologist, radiologist, physicians, pharmacist) into AI based technologies? In this session we will discuss about past, present and future of AI ( Dr, Okanohara), AI driven cell sorting (Dr. Ohta), AI based cancer treatment (Dr, Nishimura) and drug development based onintegration of multi-omics data (Dr. Han). All presentators will be young and top level active scientist from various field and countries.

Coordinator

Dr. Tatsuhiko Kodama

Cancer-Metabolism Project Leader
Research Center for Advanced Science and Technology
The University of Tokyo

Medical application of Deep Learning

Dr. Daisuke Okanohara

Representative Director & Executive Vice President
Preferred Networks, Inc.

In Japanese

Cancer Precision Medicine and Data Science

Dr. Kunihiro Nishimura

CEO
Xcoo, Inc.

In Japanese

Beyond “seeing is believing”: AI-driven imaging cell sorter (Ghost Cytomtery)

Prof. Sadao Ota

Associate Professor
Networked biophotonics and microfluidics group
Research center for advanced science and technology, the University of Tokyo

New Trend in Therapeutics Research - Artificial Intelligence for identifying novel therapeutic targets, biomarkers and drug repositioning opportunities

Dr. Namshik Han

Head of Computational Biology
Milner Therapeutics Institute
University of Cambridge

Panel discussion


Oct.11(Thu.)      13  :  30  ~  15  :  30

F202
【S-7】 Flanders Investment & Trade
Pre-Registration required Simultaneous interpretation

The 19th Belgium-Flanders Life Sciences Seminar -The life sciences eco-system in Belgium-Flanders and collaboration opportunities-

Decades of advanced knowhow, academically-trained and entrepreneurial people, and continuous innovation: these are the main ingredients that have made Flanders, the northern region of Belgium, a world leader in life sciences. More than 200 life sciences companies are working closely with universities, research institutes and hospitals. They form a mature and unique life sciences cluster in the heart of Europe. Leading organizations/companies from Flanders will participate in this seminar and demonstrate how various organizations/companies are operating a world-class research infrastructure and how they interact in a successful and efficient way to create the present strength of Belgium-Flanders in biotechnology and life sciences.

Coordinator

Dr. Ben Kloeck

Technology Director
Embassy of Belgium Flanders Investment & Trade

Sketching the Life Sciences Ecosystem in Flanders - crossing borders of technology & sectors

Willem Dhooge

flanders.bio

'VIB from Science to IMPACT’ : building a state of the art research institute in Europe

Lieve Ongena

VIB

In Japanese

Improving clinical translatability of Alzheimer’s disease mouse models

Bart Roucourt

reMYND

Novosanis a medical device company, active in diagnostics and intradermal drug delivery

Timothi Van Mulder

Novosanis

Addressing Global Clinical Trial Supply Challenges

Thomas Ockier

Andacon

Unlocking global R&D potentials, introducing transparency between corporates and universities

Francesco Ruospo

AcademicLabs

Personalised approach of doing clinical trails in Flanders

Jean Paul Deslypere

Aesculape

Streamlining the Cell Therapy Workflow with Silicon Chip Technology

Isao Kawata

Imec

In Japanese

Building the European hotspot for regenerative medicine

Jan Schrooten

RegMed

Oct.11(Thu.)      14  :  00  ~  16  :  00

F201
【S-8】 Ministry of Economy, Trade and Industry
Pre-Registration required Full Simultaneous interpretation

"Ito Review 2.0:Biomedical Edition"
-Biotech's Management Strategy for the growth after listing-

In this seminar experts including Professor Kunio Ito (Hitotsubashi University) will introduce the essence of "Ito Review 2.0: Biomedical Edition" and environmental issues on fundraising by listed biotechs. With regard to listed biotechs, a global comparison and strategies for post-IPO growth will be focused in the panel discussion.

Coordinator

Prof. Kunio Ito

Professor
Graduate School of Business Administration
Hitotsubashi University

The Background and Key Points of "Ito Review 2.0:Biomedical Edition"

Prof. Kunio Ito

Professor
Graduate School of Business Administration
Hitotsubashi University

In Japanese

10 Issues Spotted by "Ito Review 2.0:Biomedical Edition"

Mr. Keita Maeda

Deputy Director
Bio-Industry Division
Ministry of Economy,Trade and Industry

In Japanese

The Transition of Financing Environment for Biotech in Japan

Mr. Yasuyuki Konuma

Executive Managing Director (Listings)
Tokyo Stock Exchange, Inc. (TSE)

In Japanese

Fund Raising Environment for Biotech - Asia, the Advancing Market

Mr. Michael Chan

Senior Vice President
Market Development Division
Hong Kong Exchanges and Clearing (HKEX)

The Role of "Index" Connecting Emerging Companies and Institutional Investors

Mr. Yoshiyuki Makino

Head of Japan Office
S&P Dow Jones Indices

In Japanese

Towards a Better Dialogue with Institutional Investors - 1. From a pharmaceutical analyst's point of view

Mr. Atsushi Seki

Executive Director
UBS Securities Japan Co., Ltd.

In Japanese

Towards a Better Dialogue with Institutional Investors - 2. From a bio-analyst's point of view

Mr. Hironoshin Nomura

Senior Analyst
Mizuho Securities Co., Ltd

In Japanese

Panel Discussion
- The Essential Points for Biotech to Grow After Listed -

[Chair] Professor Kunio Ito (Hitotsubashi University)

In Japanese

[Panelist]

Ms. Cara Eio

Head of Asia
II Research
Institutional Investor

[Panelist]

Mr. Shohei Iwaya

Senior Fund Manager
Asset Management One Co., Ltd.

In Japanese

[Panelist]

Mr. Hidaka Shinichiro

Senior Fund Manager
Mitsubishi UFJ Kokusai Asset Management Co, Ltd.

In Japanese

[Panelist]

Mr. Masatsune Okajima

Vice President and Head of Japanese Office
MediciNova, Inc.

In Japanese

[Panelist] Mr. Atsushi Seki (UBS Securities Japan Co.,Ltd.)

In Japanese

[Panelist] Mr. Hironoshin Nomura (Mizuho Securities Japan Co.,Ltd.)

In Japanese

Organizer

Oct.12(Fri.)      11  :  30  ~  13  :  00

F205-206
【O-14】 Digital Transformation in Pharma/Healthcare
Admission Fee required Pre-Registration required Simultaneous interpretation

Digital Transformation in Pharma/Healthcare

The trend of Digital Transformation due to the innovation of the digital health has created new technologies, industries and social concepts. It is also changing the business model of the conventional pharmaceutical industry. In this session, we will introduce the business model of new players participating in digital health, and discuss how the pharmaceutical industry and medical / healthcare industry should change.
Keyword: Platform business

Coordinator

Dr. Junichi Koga

Chairperson
Biopharmaceutical Committee
The Japan Pharmaceutical Manufacturers Association

Introduction

Ms. Ide Hiroko

Deputy Director
Business Development Department
Japan Bioindustry Association

How the use of Real World Evidence can improve patient outcomes

Mr. Stefan Woxström

Representative Director and President
AstraZeneca K.K.

Connected Healthcare enabling Digital Transformation

Mr. Partha Marella

Senior Vice President, Engineering R&D Services
Global Healthcare and Medical Devices Head
HCL Technologies

InsurTech X HealthTech in Life Insurance

Mr. Yasuhiro Maenaka

Executive Officer & Vice President, Strategy Planning, Integrated Change Management
MetLife Japan

In Japanese

Panel discussion


Luncheon

Oct.12(Fri.)      12  :  00  ~  13  :  00

F204
【L-7】 Beyond Next Ventures Inc.
Pre-Registration required Full

"Blockbuster TOKYO”, an acceleration program for drug development and support using a shared wet lab

Dr. Mayu Morishima

Beyond Next Ventures Inc.

In Japanese

Oct.12(Fri.)      13  :  00  ~  14  :  00

F201
【S-12】 Intellectual Property Strategy Network Inc.
Pre-Registration required Full

"Effective Difference in Technology Transfer between Early Stage and Late Stage"
~ Toward Practical Realization and Industrialization of Seeds from Academia and Ventures

AMED's measures of Intellectual property strategy to contribute academia's seeds to patients

Mr. Kazuomi Iwatani

Managing Director
Department of Intellectual Property
Japan Agency for Medical Research and Development(AMED)

In Japanese

Mr. taro Tokita

SMBC Venture Capital Co.,Ltd 

In Japanese

IPSN’s approaches toward technology transfer of academia seeds

Mr. Akira Miyagishi

Intellectual Property Strategy Network, Inc.

In Japanese

Oct.12(Fri.)      13  :  30  ~  14  :  30

F202
【S-13】 Australian Embassy
Pre-Registration required Simultaneous interpretation

Australian Life Sciences – Engaging with the World

Coordinator

Mr. David Lawson

Consul General, Osaka
Australian Trade and Investment Commission
Australian Embassy

Regenerative Medicine Australia – Japan collaboration

Mr. Silvio Tiziani, Director, External Strategy and Planning, Australian Regenerative Medicine Institute/Chair, Regenerative Medicine Advisory Group, AusBiotech

Why Australia for medical technology and pharmaceutical (MTP)

Dr. Dan Grant

CEO
MTPConnect

Australia – a premier location for clinical trials

Ms. Jane Kelly

CEO
CMAX Clinical Research Pty Ltd

Cellular therapy delivery to patients – commercial cell manufacturing capabilities and deployment integrated within a cancer centre

Prof. Dominic Wall

Chief Scientific Officer
Cell Therapies Pty Ltd

Oct.12(Fri.)      13  :  30  ~  14  :  30

F204
【S-15】 The National Institute of Advanced Industrial Science and Technology (AIST)
Pre-Registration required Full

“Front line of the Microbiome Researches” - Drug discovery, agriculture and environment –

Microorganisms show various functions, through interacting with human, animals, plants, and microbes themselves. While it is hard to culture most microbes, AIST has developed various kinds of analytical techniques, and promotes the microbiome study for many aspects. AIST pushes forward precision management technology development and the standardization of the microbiome measurement, and supports your microbiome research and developments. Furthermore, we will introduce recent our research, for example, elucidation of the variety and function of symbiosis microbes of pests, excavation of the new functions including the recovery of energy and resources from liquid wastes, through analyses of the variety and genome information of the microbes.

Coordinator

Dr. Masanori Gotoh

Innovation Coordinator
Department of Life Science and Biotechnology
National Institute of Advanced Industrial Science and Technology (AIST)

Improving the reliability and comparability of microbiome measurements

Dr. Yuji Sekiguchi

Principal Research Manager
Biomedical Research Institute, AIST

In Japanese

Pest management by controling gut microbiota

Dr. Yoshitomo Kikuchi

Senior Researcher
Bioproduction Research Institute, AIST

In Japanese

Deciphering the wastewater sludge microbiome

Dr. Takashi Narihiro

Senior Researcher
Bioproduction Research Institute, AIST

In Japanese

Oct.12(Fri.)      13  :  30  ~  15  :  00

F205-206
【S-16】 Life Innovation Area Conference
Pre-Registration required

Keihin Coastal Area Life Innovation Special Zone Seminar
~The Way to creating an Innovative Ecosystem in the Keihin Coastal Area~

The Keihin Coastal Area hosts global companies and together they aspire to develop innovative medicines, medical equipment, and to create a health and life-science industry. This seminar's theme is "The Way to creating an Innovative Ecosystem in the Keihin Coastal Area". We welcome 3 important leaders from this special zone who work in fields such as venture and incubator driving innovation, and they will talk about the future vision of this leading area in view of the Japanese economy.

Coordinator

Mr. Mitsuru Miyata

CEO
Miyata Institute of Technologies

Mr. Kenichi Harada

Incubation and Investment Manager
KSP,Inc. (Kanagawa Science Park)

In Japanese

Mr. Akihiko Nagata

Director CFO, euglena Co.,Ltd. / CEO, Real Teck Fund

In Japanese

Dr. Kiyofumi Kaneshiro

Executive Vice President
PeptiDream Inc.

In Japanese

Panel Discussion

Coordinator and Panelists

In Japanese

Oct.12(Fri.)      14  :  45  ~  16  :  45

F202
【S-18】 Japan Agency for Medical Research and Development
Pre-Registration required

The First Success Story (Medical Technology) of Medical Research and Development Programs Focused on Technology Transfer: Acceleration Transformative Research for Medical Innovation (ACT-M/MS)

Coordinator

Dr. TSUTOMU CHIBA

President, Kansai Electric Power Hospital; Emeritus Professor, Kyoto University; Visiting Professor, Kobe University; Chair, Committee of Intractable Disease, Ministry of Health, Welfare and Labor, Japan Program Officer

Dr. Kazuhiko Yamamoto

Deputy Director, Team leader
Laboratory for Autoimmune Diseases
RIKEN Center for Integrative Medical Sciences


In Japanese

Novel rapid identification and quantification method of bacteria in a septic blood sample

Dr. Hideki Niimi

Associate Professor
University of Toyama

In Japanese

Development of newly invented cochlear implant (artificial auditory epithelium) for the treatment of senile deafness.

Dr. Juichi Itoh

Shiga Medical Center Research Institute

In Japanese

Development of next-generation artificial pancreas as innovative option for the treatment of diabetes

Dr. Akira Matsumoto

Associate Professor
Institute of Biomaterials and Bioengineering
Tokyo Medical and Dental University

In Japanese

Development of Medical Imaging Projection System for real-time navigation liver surgery

Dr. Satoru Seo

Research associate
Department of Surgery, Graduate School of Medicine
Kyoto University

In Japanese

Oct.12(Fri.)      14  :  45  ~  16  :  45

F204
【S-19】 Japan Agency for Medical Research and Development
Pre-Registration required Full

The First Success Story (Drug Discovery) of Medical Research and Development Programs Focused on Technology Transfer: Acceleration Transformative Research for Medical Innovation (ACT-M/MS)

Coordinator

Dr. TSUTOMU CHIBA

President, Kansai Electric Power Hospital; Emeritus Professor, Kyoto University; Visiting Professor, Kobe University; Chair, Committee of Intractable Disease, Ministry of Health, Welfare and Labor, Japan Program Officer

Dr. Seiichi Tanida

Adviser
Industry-Academia-Government Collaboration Business Division Kyoto Lifetech Innovation Support Center
Advanced Science, Technology & Management Research Institute of KYOTO

Development of Novel Cancer Therapy Based on Dual Inhibition of EZH1/2

Dr. Issay Kitabayashi

Chief
Division of Hematological Malignancy
National Cancer Center Japan

In Japanese

Development of an innovative anti-fibrotic agent for cirrhosis of type C

Dr. Kiminori Kimura

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

In Japanese

Novel tailor-made therapy for adult T-cell leukemia/lymphoma

Dr. Daisuke Morishita

Senior Director Biology
Chordia Therapeutics,Inc.

In Japanese

Development of Opioid Delta Receptor Agonist Modulating Emotional System

Dr. Eriko Nakata

Manager
Discovery Laboratory2, Discovery Research Laboratories
Nippon Chemiphar

In Japanese

Oct.12(Fri.)      15  :  00  ~  16  :  00

F203
【S-20】 Hokkaido
Pre-Registration required

Hokkaido Program

Coordinator

Hokkaido

Hokkaido University

In Japanese

KAMUi Pharma, Inc.

In Japanese

Toko Pharmaceutical Industries Co.,Ltd.

In Japanese

Organizer

Oct.12(Fri.)      15  :  30  ~  17  :  00

F201
【O-15】 Current of Cancer Genome Medicine
Admission Fee required Pre-Registration required Full Simultaneous interpretation

Current of Cancer Genomic Medicine

Social implementation of the cancer genomic medicine based on genome sequence analysis is an urgent issue in Japan. In this session, we introduce preceding overseas efforts and survey the role of the companies in effective cancer genomic medicine.

Coordinator

Prof. Satoru Miyano

Professor
Human Genome Center, Institute of Medical Science
University of Tokyo

Overview

Prof. Satoru Miyano

Professor
Human Genome Center, Institute of Medical Science
University of Tokyo

Genomics England: Leading the healthcare revolution using clinical and genomic data

Prof. Joanne Hackett

Chief Commercial Officer
Genomics England

Clinical Next-Generation Sequencing in Oncology

Mr. Jee-Hian Lim

Senior Market Development Manager, Asia Pacific
Illumina Inc

Clinical Interpretation of Somatic Cancer

Ms. Shoba Anantha

IBM Watson Health

Panel discussion


Organizer

Oct.12(Fri.)      15  :  30  ~  17  :  00

F205-206
【O-16】 The Future Health System
Admission Fee required Pre-Registration required Simultaneous interpretation

The Future Health System

Trends in Digital Transformation due to digital health innovation have created not only new technologies and industries, but also the concept of well-being beyond traditional medical. In this session, we introduce the initiatives of Global Digital Health Partnerships, Digital Health Society, and data health advances such as Australia, Northern Europe, Southern Europe, etc. from the viewpoint of data health. We will also discuss changes that the Digital Health Society brings.

Coordinator

Prof. Hiroaki Miyata

Professor
Department of Health Policy and Management
School of Medicine,Keio Univercity

Introduction

Prof. Hiroaki Miyata

Professor
Department of Health Policy and Management
School of Medicine,Keio Univercity

Challenges to Digital Health Society in Japan

Ms. MARI YAMAMOTO

Councillor for the Minister
Minister's Secretariat
Ministry of Health,Labour and Welfare

In Japanese

Mr. Andrew Casey

President & CEO
BIOTECanada

Connected Health Cities: A UK perspective on implementing learning health systems at scale

Dr. Gary Leeming

CTO
Connected Health Cities

Panel discussion


Luncheon

Oct.10(Wed.)      12  :  00  ~  13  :  00

F202
【L-2】 Embassy of Canada to Japan
Pre-Registration required Full

The 9th Canada Life Sciences Seminar @BioJapan2018
Investment and Business Opportunities in Regenerative Medicine - Canadian Landscape and Success Story

Canada is one of the leaders in regenerative medicine innovation. Since the team of Drs. James Till and Ernest McCulloch discovered the stem cell in 1961, Canada has been a hotbed of ground-breaking innovations in regenerative medicine. One such example is the work of Dr. John E. Dick of Toronto University, who last year received the prestigious Keio Medical Science Prize for his research on cancer stem cells. Canada's support of a wide range of research and development and commercialization of research in regenerative medicine through investment at the federal and provincial levels combined with various tax incentives and the availability of highly educated talent, makes Canada an attractive destinations for your business and investment.
This seminar will provide an overview of regenerative medicine reserach, development and commercialization in Canada. The seminar will feature the Vice President of the National Research Council (NRC), who will discuss the landscape of regenerative medicine research and introduce NRC programs supporting research and commercialization.
The seminar will also feature a Canadian start-up company, Aspect Biosystems that develops bio-printing technology to address challenges in regenerative medicine.

Opening Remarks: Overview of Canada's Biotech Industry

Mr. Andrew Casey

President and CEO
BIOTECanada

Regenerative Medicine Landscape in Canada

Dr. Roman Szumski

Vice-President (Life Sciences)
National Research Council of Canada (NRC)

Enabling the Creation of Human Tissues on Demand through Strategic Partner Engagement and Ecosystem Development - Aspect Biosystems Inc.

Mr. Tamer Mohamed

President and CEO
Aspect Biosystems Inc.

Organizer

Oct.10(Wed.)      15  :  00  ~  16  :  30

F205-206
【O-3】 Latest approaches by Japanese companies in regenerative medicine
Admission Fee required Pre-Registration required Simultaneous interpretation

Latest approaches by Japanese companies in regenerative medicine

Latest approaches for regenerative medicine will be presented by the representatives of Japanese companies.

Coordinator

Mr. Hidenori Kanno

Chair, Steering Committee
Forum for innovative Regenerative Medicine

Research and Development of Implant-type Regenerated Cartilage(Regenerative Medeicine Products)
Utilizing Auto-auricular Tissue Derived Chondrocytes and its Application to Cleft Lip-nose Deformity Treatment for Patients with Cleft Lip And Palate

Mr. Motohiro Harai

Director & Executive Operating Officer & COO
Regenerative Medeicine Research
FUJI SOFT INCORPORATED

In Japanese

R&D on Regenerative Medicine and Cell Therapy in KANEKA

Dr. Yasuyoshi Ueda

Executive Officer, General Manager
Regenerative Medicine and Cell Therapy Laboratories
KANEKA Corporation

In Japanese

Introduction of a Japanese style incubation for medical innovation

Dr. Takahiro Uchida

CEO
Japanese Organization for Medical Device Development, Inc.

In Japanese

Organizer

Oct.11(Thu.)      9  :  30  ~  11  :  00

F205-206
【O-5】 Administrative activities on promoting the industrialization of regenerative medicine
Admission Fee required Pre-Registration required Simultaneous interpretation

Administrative activities on promoting the industrialization of regenerative medicine

Representatives from administrative ministries and organization introduce their activities on promoting the industrialization and perspectives. The session presents lectures, followed by panel discussion.

Coordinator

Mr. Kunihiko Suzuki

Vice Chairman, Member of the Board, Forum for Innovative Regenerative Medicine / Vice Chairman, MEDINET Co., Ltd.

Research Promotion Policy of MEXT for Regenerative Medicine

Mr. Hideshi Semba

Director
Life Sciences Division
Ministry of Education, Culture, Sports, Science and Technology (MEXT)

In Japanese

Overview of the Act on the Sfety of Regenerative Medicine

Mr. Haruhiko Hakuno

Maneger
Research and Development Division
Ministry of Health Labour and Walfare

In Japanese

Policy development of the Ministry of Economy, Trade and Industry toward industrialization of regenerative medicine~Acceleration of product development and biotech support~(TBD)

Mr. Masahiro Uemura

Director, Bio-Industry Division, Commerce and Service Industry Policy Group
the Ministry of Economy, Trade and Industry

In Japanese

AMED Regenerative Medicine Research Project

Ms. Yuka Suzuki

Director
Division of Regenerative Medicine Research, Department of Research Promotion
Japan Agency for Medical Research and Development

In Japanese

Panel discussion


Oct.11(Thu.)      13  :  15  ~  14  :  45

F205-206
【S-6】 TAKARA BIO INC.
Pre-Registration required Full

Commercialization and related issues on development of regenerative medicine, cell and gene therapy products

In the context of regenerative medicine / gene therapy products, the development of which is accelerated in Japan, in this seminar we will have talk by leading experts, focusing on fundamental research of iPS cells and gene therapy getting closer to practical use. In addition, we introduce Takara Bio's technologies relating to gene therapy and our CDMO business.

Introduction

Dr. Junichi Mineno

Managing Director, President of Bioindustry Business Unit
Takara Bio Inc.

In Japanese

The most recent findings on human naïve iPS cells toward practical applications

Dr. Yasuhiro Takashima

Junior Associate Professor
Center for iPS Cell Research and Application, Kyoto University

In Japanese

Updates on development of cell & gene therapies in the world toward practical use, and its related issues

Dr. Masafumi Onodera

Head
Department of Human Genetics
National Center for Child Health and Development

In Japanese

Manufacturing and quality control for regenerative medicine / cell and gene therapy products

Dr. Hideto Chono

General Manager
CDM Center Division 2
Takara Bio Inc.

In Japanese

Oct.11(Thu.)      15  :  00  ~  17  :  00

F203-204
【S-9】 Foundation for Biomedical Research and Innovation at Kobe
Pre-Registration required Full Simultaneous interpretation

Kobe Biomedical Innovation Cluster 20th anniversary - Heralding a new era in healthcare -

Coordinator

Dr. Hiramatsu Ryuji

Executive Coordinator
Center for Cluster Development and Coordination
Foundation for Biomedical Research and Innovation at Kobe

Creating a center of intelligence for medical innovation

Dr. Tasuku Honjo

President
Foundation for Biomedical Research and Innovation at Kobe

In Japanese

Aiming for global standards of regenerative medicine
- Challenge of Research & Development Center for Cell Therapy -

Dr. Shin Kawamata

Director
Research & Development Center for Cell Therapy
Foundation for Biomedical Research and Innovation at Kobe

In Japanese

Shiseido’s Approach to Hair Regenerative Medicine

Mr. Masashi Ogo

General Manager for Incubation Center
Global Innovation Center
Shiseido Co., Ltd.

In Japanese

Collaboration on new medical device applications for ”TITANBRIDGE”,designated for SAKIGAKE examination in Japan, and future overseas deployment

Mr. Shigeki Shimasaki

Vice president & COO, Head of Research & Development
Research&Development
Nobelpharma Co.,Ltd.

In Japanese

Organizer

Oct.11(Thu.)      15  :  30  ~  17  :  00

F205-206
【O-9】 Update in iPS Cell Research
Admission Fee required Pre-Registration required Full Simultaneous interpretation

Update in iPS Cell Research

We will illustrate the progress in iPS cell Research, especially focusing on clinical studies with allo iPS cell Stock in Japan, and will discuss on the problems and solutions to bring iPS cell derived tissues or cells to paitients.

Coordinator

Prof. Mitsuru Miyata

CEO
Miyata Institute of Technologies

Recent Progress in iPS Cell Research and Application

Prof. Shinya Yamanaka

Director/Professor
Center for iPS Cell Research and Application (CiRA), Kyoto University

In Japanese

Development of iPS derived Cardiac Cell Sheet

Prof. Yoshiki Sawa

Professor and Chairman
Department of Cardiovascular Surgery
Osaka University Graduate School of Medicine

In Japanese

Panel discussion


Organizer

Oct.12(Fri.)      9  :  30  ~  11  :  15

F205-206
【O-12】 Emerging Technology Start-ups in Regenerative Medicine
Admission Fee required Pre-Registration required Simultaneous interpretation

Emerging Technology Start-ups in Regenerative Medicine

Start-up companies play important roles in innovating regenerative medicine. In this session, 3 start-ups will introduce their advanced technologies and products.

Coordinator

Dr. Seigo Izumo

Director, Forum for Innovative Regenerative Medicine / Global Head of Regenerative Medicine Unit, Takeda Pharmaceutical Company Limited

Clinical Trial Results of the World’s First iPSC-derived MSC Therapeutic Product

Dr. Ross Macdonald

Managing Director and Chief Executive Officer
Cynata Therapeutics Limited

Using the Magnelle(R) Cell Labeling and Tracking Platform: Understanding In Vivo Cell Tracking for Injection Targeting, Localization and Durability to Improve Study Design

Mr. Kenneth Harris

President & CEO
Bell Biosystems, Inc.

Process development for platelet production from human iPS cells

Dr. Kenichi Akamatsu

Chief Operating Officer
Megakaryon Corporation

In Japanese

Advanced Therapy Medicinal Products (ATMP) for deeper and longer lasting immune therapy of cancer

Prof. Farzin Farzaneh

Chair of Molecular Medicine, and Director of Cell & Gene Therapy - King's
Molecular Medicine
King's College London

Oct.12(Fri.)      13  :  30  ~  14  :  30

F203
【S-14】 Nikon CeLL innovation Co., Ltd. / Lonza Japan
Pre-Registration required Full

Enabling Cell and Gene Therapy on a Global Scale
-Partnering to offer excellence in regenerative medicine CDMO services

The cell and gene therapy market has experienced an immense growth driven by recent landmark approvals and commercial launches. While these products are showing remarkable therapeutic efficacy, there is an emerging need for manufacturing platforms and solutions to allow for production at scale to meet market demand globally, reduce costs resulting in commercially viable therapies and achieve consistent product of highest quality and safety. Lonza will outline the specific challenges development and manufacturing of these groundbreaking therapies are facing and provide solutions how innovative platforms and solutions may help overcome some of the issues faced by the industry.
Nikon CeLL innovation will introduce GCTP/cGMP compliant CDO/CMO facility and its services located in Tokyo, under Nikon-Lonza Partnership.

Cell and gene therapy: what’s next ....

Dr. Thomas Fellner

Head of cell and gene therapy
Pharma & Biotech
Lonza

CDMO Facility Introduction of Nikon CeLL innovation Co., Ltd.

Mr. Toshiyuki Nakayama

President
Nikon CeLL innovation Co., Ltd.

In Japanese

Organizer

Oct.10(Wed.)      15  :  30  ~  17  :  00

F203-204
【O-4】 global trend of healthcare innovation for super-aged society in Japan and the world ~with report of 1st Well Aging Society Summit Asia-Japan~
Admission Fee required Pre-Registration required Simultaneous interpretation

global trend of healthcare innovation for super-aged society in Japan and the world ~with report of 1st Well Aging Society Summit Asia-Japan~

We will present an overview of "1st Well Aging Society Summit Asia-Japan" held on October 9th the day before this seminar. We will announce global innovation that will contribute to super-aged society by reviewing the products and services from companies participated in the above summit. We will also talk about global issues on super-aged society such as dementia with experts from the world such as Japan, the US and Europe and discuss the direction of each country's efforts and problem solving by panel discussion.

Coordinator

Mr. Kazumi Nishikawa

Director
Commerce and Service Industry Policy Group
Ministry of Economy, Trade and Industry

Panel discussion


[Moderator]

Dr. Kiyoshi Kurokawa

Chairman, Health and Global Policy Institute / Professor Emeritus, National Graduate Institute for Policy Studies

[Panelist]

Ms. Annika Saarikko

Minister of Family Affairs and Social Services, Finland

Dr. Dessislava Dimitrova

Practice Lead, Health Systems Transformation, Health and Healthcare, World Economic Forum

Dr. John Beard

Director of Ageing and Life Course
World Health Organization

Prof. Takeshi Iwatsubo

Professor
Department of Neuropathology, Graduate School of Medicine
University of Tokyo

In Japanese

Dr. Teiji Kimura

Vice President,
Eisai Co., Ltd.

In Japanese

Mr. Mikio Okumura

Managing Executive Officer,
SOMPO holdings, Inc.

In Japanese

Oct.11(Thu.)      10  :  15  ~  12  :  15

Main Stage
【M-1】 Cross-ministerial Strategic Innovation Promotion Program (SIP): Technologies for Creating Next-Generation Agriculture, Forestry and Fisheries Development of Next-Generation Functional Agriculture, Forestry and Fishery Products and Foodstuffs
Pre-Registration not required

Coordinator

Prof. Keiko Abe

The University of Tokyo

Dr. Keiko Abe

The University of Tokyo

In Japanese

Dr. Asuka Kamei

Kanagawa Institute of Industrial Science and Technology

In Japanese

Dr.

Graduate School of Agricultural and Life Sciences, The University of Tokyo

In Japanese

WASEDA University

In Japanese

Ms. Kimiko Kazumura

Hamamatsu Photonics K.K.

In Japanese

Organizer

Oct.12(Fri.)      9  :  30  ~  11  :  00

F201
【O-10】 Healthcare industry based on scientific evidence
Admission Fee required Pre-Registration required Simultaneous interpretation

Healthcare industry based on scientific evidence

In the super aged society we are facing, it is required to build a society that can live healthy and active lives for a long time. For that, healthcare before getting illness is important. Particularly, it is urgent to take measures against "Frailty" which causes mental and physical weakness and "Sarcopenia" which causes a decline in activity due to a decrease in muscle mass. However, factors causing "Frailty" and "Sarcopenia" are not single, and in order to prevent them it is necessary to clarify the relationship with various factors in daily life. Various research activities and scientific approaches have been made to solve this. Lecture from these various experts, deepen the understanding of healthcare for "Frailty" and "Sarcopenia" and discuss how to scientifically do to develop healthcare business.

Coordinator

Dr. Katsunori Matsuoka

Vice-President, Director General, Department of Life Science and Biotechnology
National Institute of Advanced Industrial Science and Technology

Prevention and management of frailty and sarcopenia in a super-aged society

Dr. Hidenori Arai

Director
National Center for Geriatrics and Gerontology

In Japanese

Using linked, integrated 'big data' to assess opportunities to improve health outcomes in the frail and sarcopenic

Ms. Sara Sekelj

Data Analyst
Imperial College Health Partners

Frailty prevention measures of Kashiwa City

Ms. Yukiko Takagi

Assistant Director
Kashiwa City Health and Welfare Department Community Comprehensive Support Division 

In Japanese

Health care at home【TALK/FOOD/DYNAMIC/SLEEPING】

Dr. Atsushi Uetake

Sinior Manager
HAUSING PRODUCT RESEARCH & DEVELOPMENT DEPARTMENT
SEKISUI CHEMICAL CO.,LTD.

In Japanese

Organizer

Oct.12(Fri.)      11  :  15  ~  12  :  45

F201
【O-13】 Diets and gut microbiota in the control of health and diseases
Admission Fee required Pre-Registration required Simultaneous interpretation

Diets and gut microbiota in the control of health and diseases

Accumulating evidence has indicated that microbiota coexisting in humans especially gut commensal bacteria regulate the development of disease and thus we now recognized the importance of commensal bacteria in the maintenance and promotion of human health. We also know that diets play a key role in the control of our body condition. In addition to their direct interaction with host, the interaction between diets and microbiota is another importance factor. Current advances in analytical technologies allow the providing new knowledge based on scientific evidence. In this session, we will introduce the cutting-edge information and discuss the future direction on this field.

Coordinator

Dr. Jun Kunisawa

Project leader
National Institutes of Biomedical Innovation, Health and Nutrition

Dr. Jun Kunisawa

Project leader
National Institutes of Biomedical Innovation, Health and Nutrition

In Japanese

Dietary interventions in gastrointestinal diseases

Dr. Jia Li

Senior Lecturer
Surgery and Cancer
Imperial College London

Toward understanding the function of gut microbiota and creating a novel healthcare industry based on intestinal design

Dr. Shinji FUKUDA

Project Associate Professor
Institute for Advanced Biosciences
Keio University

In Japanese

Breast Milk Components Affecting Gut Microbiota Development and a Key Genetic Factor of Bifidobacteria

Dr. Takahiro Matsuki

Manager, Senior Researcher
Basic Research Department
Yakult Central Institute

In Japanese

Luncheon

Oct.12(Fri.)      12  :  00  ~  13  :  00

F202
【L-5】 Kanagawa Prefectural Government
Pre-Registration required Full

From Kanagawa! Formulating Open Innovation Hub for Innovative Healthcare Technology
-Cooperation of Tonomachi and Shonan iPark: Focusing on Regenerative Medicine-

Kanagawa Prefectural Government and Takeda Pharmaceutical Company Ltd. concluded MOU regarding cooperation in healthcare fields in April 2018, and implementing sevral projects for realizing innovative healthcare technologies. This seminar introduce Research Complex Program including Life Innovation Center in Tonomachi area and Shonan Health Innovation Park (iPark), and discuss open innovation for practical use of innovative healthcare technologies. We also present future cooperation between Tonomachi and Shonan iPark.

Coordinator

Organizer
Research Complex Program

Activities of the Research Complex in Tonomachi towards future innovation ecosystem

Prof. Ryota Yoshimoto

Organizer
Research Complex Program

In Japanese

Regulatory science for ensuring quality, safety and efficacy of cell therapy products

Dr. Yoji Sato

Head
Division of Cell-Based Therapeutic Products
National Institute of Health Sciences

In Japanese

To create Hotspot in Japan: the role of Shonan iPark

Dr. Toshio Fujimoto

General Manager
Shonan Health Innovation Park
Takeda Pharmaceutical Co., Ltd.

In Japanese

Direction of Inter-Hub Cooperation amang Tonomachi and Shonan iPark (tentative)

Mr. Nobutaka Kanai

Director General
Kanagawa Prefectural Government

In Japanese

Oct.10(Wed.)      13  :  00  ~  15  :  00

F203-204
【S-1】 New Energy and Industrial Technology Development Organization
Pre-Registration required

New Energy and Industrial Technology Development Organization
NEDO seminer

New Strategy for Bioeconomy Development in Japan

Mr. Masahiro UEMURA

Director
Bio-industry Division, Commerce and Service Industry Policy Group
Ministry of Economy, Trade, and Industry, Japan

In Japanese

Mr. Noriaki KOBAYASHI

Program Director
Council for Science, Technology and Innovation
Cabinet Office, Government of Japan

In Japanese

A new era of bioindustry based on the smart cell creation platform

Prof. Satoru KUHARA

Professor emeritus
Kyushu University

In Japanese

Recent advances in plant biotechnology for useful material production

Prof. Takeshi Matsumura

Research group leader
National Institute of Advanced Industrial Science and Technology

In Japanese

Development of smart cell construction platform for next-generation microbial breeding

Prof. Tomohisa HASUNUMA

Professor
Kobe University

In Japanese

Ms. Chikako HAYASHI

Project Manager
Materials Technology and Nanotechnology Dept.
New Energy and Industrial Technology Development Organization

In Japanese

Luncheon

Oct.12(Fri.)      12  :  00  ~  13  :  00

F203
【L-6】 TAKARA BIO INC.
Pre-Registration required Full

Single-cell research: Advances and applications

Coordinator

Takara Bio Inc.

Single-cell research: Advances and applications

Yutaka Suzuki

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo

In Japanese

SMARTer ICELL8 cx- an integrated imaging and targeted dispensing platform for your single cell analysis: See more discover more!

Dr. Prashant Wani

Takara Bio USA, Inc.

Organizer

Oct.12(Fri.)      10  :  15  ~  11  :  45

Main Stage
【M-3】 Cellulose Nano-Fiber
Pre-Registration not required Simultaneous interpretation

Cellulose Nano-Fiber: Its characteristics and challenges as a high-functional nano-materials based on biomass

Cellulose Nano-Fiber (CNF) has the unique structure and characteristics as a new nano-material based on biomass. Currently, expected demands of CNF on multipurpose utilization for high performance and value-added products is increasing from various fields. On the other hand, variation of structure and characteristics of CNF samples derived from preparation methods should be considered toward proper adaptation in its marketing. In this seminar, the latest information on fundamental research and technical development on CNF will be presented and the challenges on application of CNF will be discussed.

Coordinator

Prof. Masahiro Samejima

Professor
Department of Biomaterial Sciences, Graduate School of Agricultural and Life Sciences
The University of Tokyo

Cellulose nanofiber: Unique characteristics and future challenges as highly functional bionanomaterials

Prof. Akira Isogai

Professor
Department of Biomaterial Science, Graduate School of Agricultural and Life Sciences
The University of Tokyo

In Japanese

Structure and Functionarity of Cellose Nanofaiber Nonwoben Sheet

Dr. Hirofumi Ono

Manager, Lead Expart
Fiber & Textiles SBU, R&D Laboratory for Fibers & Textiles Technology
Asahi Kasei Corporation

In Japanese

Applications of "RHEOCRYSTA" cellulose nanofibers with thickening, emulsifying and dispersing properties

Mr. Yohsuke Goi

Specialist
Rheocrysta R&D Group Life Science R&D Department R&D Headquarters
DKS Co. Ltd.

In Japanese

Interfacial control of TEMPO-oxidized cellulose nanofibers

Dr. Yoshiaki Kumamoto

Senior Maneger
Material Science Research
Kao Corporation

In Japanese

Organizer

Oct.12(Fri.)      12  :  00  ~  13  :  30

Main Stage
【M-4】 Bioindustry in a sustainable society
Pre-Registration not required Simultaneous interpretation

Bioindustry in a sustainable society

Coordinator

Dr. Yoichi Kamagata

Deputy Director General
Department of Life Science and Biotechnology
National Institute of Advanced Industrial Science and Technology (AIST)

To realize sustainable society
~ Digital BioEconomy ~

Mr. Wataru Mizunashi

General Manager, Biotechnology
Tokohama R&D Center
Mitsubishi Chemical Corporation

In Japanese

Current challenges in biotechnology for hydrogen economy

Dr. Takashi Narihiro

Senior Research Scientist
Bioproduction Research Institute
National Institute of Advanced Industrial Science And Technology (AIST)

In Japanese

NEDO's activities for Energy conservation technology development and method of potential estimation

Mr. Toshiya Imada

Director General
Energy Conservation Technology Department
New Energy and Industrial Technology Development Organization

In Japanese

Panel discussion


Organizer

Oct.10(Wed.)      14  :  30  ~  17  :  00

F202
【A-1】 Japan Bioindustry Award, Bioindustry Research Award 2018 Ceremony, Award Lecture and Poster Session
Pre-Registration required Simultaneous interpretation

Japan Bioindustry Award, Bioindustry Research Award 2018 Ceremony, Award Lecture and Poster Session

Japan Bioindustry Association (JBA) celebrated the 30th anniversary of its foundation last year. Concomitantly with this anniversary, JBA evolved previous awards to newly established "Japan Bioindustry Award" and "Bioindustry Research Award". The Japan Bioindustry Award is given to an incomparable work which has contributed significantly to bioindustry's development or envisaging significant industry development in near future. The Bioindustry Research Award is given to young researchers engaged in outstanding research activities appreciating practical application potentials. Ceremony of both the Japan Bioindustry Award and the Bioindustry Research Award will be held with award lecture by the winner of Japan Bioindustry Award. There will also be poster presentations by ten winners of the Bioindustry Research Award.

【Japan Bioindustry Award Winner】Development of biologics for asthma based on discovery of IL-5/IL-5 receptor

Prof. Kiyoshi Takatsu

Director
Toyama Prefectural Institute for Pharmaceutical Research

In Japanese

【Bioindustry Research Award Winner】Establishment of new functional lipids based on lipid metabolism analysis of intestinal bacteria

Mr. Shigenobu Kishino

Associate Professor
Graduate School of Agriculture
Kyoto University 

In Japanese

【Bioindustry Research Award Winner】Gut-initiated control of immunological environment as a new era of healthcare science

Mr. Jun Kunisawa

Project leader
Laboratory of Vaccine Materials and Laboratory of Gut Environmental System
National Institutes of Biomedical Innovation, Health and Nutrition

In Japanese

【Bioindustry Research Award Winner】Generation of hepatocytes and enterocytes from human pluripotent stem cells for pharmaceutical research

Mr. Kazuo Takayama

Assistant Professor 
Graduate School of Pharmaceutical Sciences
Osaka University

In Japanese

【Bioindustry Research Award Winner】Development of glycan profiling technology and application to regenerative medicine and drug discovery

Mr. Hiroaki Tateno

Chief Senior Researcher
Biotechnology Research Institute for Drug Discovery
National Institute of Advanced Industrial Science and Technology 

In Japanese

【Bioindustry Research Award Winner】Wastewater treatment and ethanol fermentation by the Antarctic yeast

Mr. Masaharu Tsuji

Project Researcher
Biology group
National Institute of Polar Research

In Japanese

【Bioindustry Research Award Winner】Engineering phosphorus metabolic pathway for a biosafety strategy of genetically modified organisms

Mr. Ryuichi Hirota

Associate professor
Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter
Hiroshima University

In Japanese

【Bioindustry Research Award Winner】Development of “electronics-free” and totally synthetic artificial pancreas

Mr. Akira Matsumoto

Associate Professor
Institute of Biomaterials and Bioengineering
Tokyo Medical and Dental University

In Japanese

【Bioindustry Research Award Winner】Non-template-dependent sequence regulation of bacterial polyesters

Prof. Ken’ichiro Matsumoto

Professor
Applied Chemistry, Graduate School of Engineering
Hokkaido University 

In Japanese

【Bioindustry Research Award Winner】Fundamental study for elucidation of the molecular mechanisms of plant parasitism in Orobanchaceae

Ms. Satoko Yoshida

Associate Professor
Graduate School of Science and Technology, Division of Biological Science
Nara Institute of Science and Technology

In Japanese

【Bioindustry Research Award Winner】Construction of a single-cell analysis system for cancer genome medicine

Prof. Tomoko Yoshino

Professor
Division of Biotechnology and Life science, Institute of Engineering
Tokyo University of Agriculture and Technology

In Japanese

Oct.11(Thu.)      10  :  00  ~  11  :  50

F203-204
【S-5】 Ministry of Health, Labour and Welfare
Pre-Registration required Full Simultaneous interpretation

Japan Healthcare Venture Summit JHVS International Symposium

Dr. Wang Dan

Johnson & Johnson Innovation, Asia Pacific

Dr. Viana Amelia

Boehringer Ingelheim International GmbH

MHLW / Health Policy Bureau, Economic Affairs Division, Venture Support Strategy Office / Director

In Japanese

Dr.

Managing Director, Honjo International / Chairperson of the Council for Fostering Medical Ventures

In Japanese

Axcelead Drug Discovery Partners, Inc.

In Japanese

Johnson&Johnson Innovation

In Japanese

Nippon Boehringer Ingelheim Co.,Ltd.

In Japanese

Health2.0 Director-Japan

In Japanese

Luncheon

Oct.11(Thu.)      11  :  30  ~  13  :  00

F205-206
【L-3】 Shonan Health Innovation Park
Pre-Registration required Full Simultaneous interpretation

Creating a stage that all innovators can aim the world
-Shonan iPark's challenge-
iPark will externally present its medium term strategy for the first time. A world leading industrial cluster organizer from Boston, US, will provide the latest information on open innovation. Through lectures and discussions, iPark aims to externally communicate methods in which it could help to create a groundbreaking innovation ecosystem in Japan.

Coordinator

Prof. Shinya Sakuma

Project Professor
Graduate School of Media and Governance
Keio University

Creating a stage that all innovators can aim the world
-Shonan iPark's challenge-

Dr. Toshio Fujimoto

General Manager
Shonan Health Innovation Park

In Japanese

Why a Science Park? What Are the Goals and How to Achieve Them?

Mr. Tim Rowe

CEO
Cambridge Innovation Center (CIC)

In Japanese

–JLABS – Catalyzing Innovation to Deliver Transformational Solutions to People Globally–

Dr. Sharon Chan

Head
JLABS @ Shanghai
Johnson & Johnson Innovation

Panel Discussion

All presenters

In Japanese

Organizer

Oct.11(Thu.)      13  :  45  ~  15  :  45

Main Stage
【M-2】 Bio-cluster Summit 2018
Pre-Registration not required

Bio-cluster Summit 2018 - Global Health Data Sharing

Many countries are emphasizing biocluster policies. We will discuss together about the specific issues of biocluster policies among people concerned with bio-related policies of representative bioclusters of Japan, USA, the various countries of Europe, and Asian countries. We expect them towards international knowledge exchange among bioclusters in the world. This year we will discuss international health data sharing

Coordinator

Dr. TSUNEAKI SAKATA

President, All Japanese Bio Regions Committee / Vice President, Kinki Bio-industry Developent Organization

Balance Between Innovation and Risk Management on Cross-Border Health Data Sharing

Dr. Eiji Sasahara

Partner
Healthcare Cloud Initiative, NPO

In Japanese

Health Data in Denmark

Mr. Niels Thun Andersen

Business Development Manager,
Copenhagen Capacity

Finnish Advanced Health Ecosystem based on Data and Digitalization

Dr. Sinikka Salo

Leader of Change in reforming social welfare and healthcare in Finland
Department of Steering
Ministry of Social Affairs and Health, Governement of Finland

Mr. Raul Allikivi

Executive Director
Japan & Estonia EU Association for Digital Society Former Estonian Ministry of the Economic Affairs and Communications Officer

An introduction to the health science data environment within the UK - a lifetime of patient data enabling research and development

Ms. Sarah Haywood

CEO
MedCity

The Opportunities and Challenges Associated with Global Population Growth: A Canadian Biotech perspective

Mr. Andrew Casey

President & CEO
BIOTECanada

Taiwan Cancer Proteogenomics Moonshot: Roadmap to Next-generation Precision Medicine.

Prof. Yu-Ju Chen

Research Fellow and Director
Institute of Chemistry, Academia Sinica

In the Kawasaki City Area, the Agglomeration of Life Science Research Institutes and Industries, and the Creation of Drug Discovery Business for Peptides and Nucleic Acids using IT

Dr. YUTAKA KONO

Life Science Chief Coordinator
KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION

Development of the Life Science Industry in Osaka

Mr. Kazuhide Nomura

Associate Director
Department of Commerce, Industry and Labor Growth Industry Promotion Office,Life Sciences Industry Division
Osaka Prefectural Government

Oct.11(Thu.)      16  :  00  ~  16  :  30

F202
【S-10】 Organization for Small & Medium Enterprises and Regional Innovation, JAPAN
Pre-Registration required Full Simultaneous interpretation

Support for SMEs and Venture Business of Life Science Sector through Venture Fund(Introduction of Global Alliance Scheme)

Introduction of "Axil Life Science & Healthcare Fund" that specializes in biomedical & healthcare technology investments, with emphasis on supporting the growth of early stage ventures. They aims to find new seeds from academia and to support global development of its business through collaboration with the international companies.

SMRJ and JETRO also will explain the support scheme of "Global Alliance" that push such kind of effort for promoting investment to Japan.

Mr. Shane Frederick

Managing Partner
Axil Capital Partners,LLP

Mr. Eisuke Sakamoto

Manager
Fund Management Dept.
SMRJ

In Japanese

Mr. Jun Osawa

Deputy Director
Invest Japan Business Support Center
JETRO

In Japanese

Organizer

Oct.12(Fri.)      9  :  30  ~  11  :  00

F203-204
【O-11】 Genome editing: Commercialization framework development, and efforts linking genomic information to stakeholder value.
Admission Fee required Pre-Registration required Simultaneous interpretation

Genome editing: Commercialization framework development, and efforts linking genomic information to stakeholder value.

For commercialization and effective social implementation of products developed through genome editing, 1) science-based and transparent regulations, 2) IP environment which encourages more players entering to the field, and 3) sound and unique ideas which connect genomic information to diverse consumer values are indispensable. Regulatory considerations and IP discussion are in progress globally. Therefore, looking into the future, ideas on how to make the most advantage of genome editing techniques not in the area of agriculture but also in pharmaceuticals and industrial products would become crucial for business. In this session, we first review the environment surrounding commercialization of genome-edited products in the world, especially in EU. Then, we will discuss opportunities and possibilities that the genome editing techniques bring to our future by introducing ideas and efforts in connecting genomic information with products which provide values to various stakeholders.

Coordinator

Dr. Mieko Kasai

Professor
Center for Environment, Health and Field Sciences
Chiba University

Genome Editing in Europe: Status and future prospects

Dr. Ricardo Gent

Executive Director
German Association of Biotechnology Industries (DIB)

New era of high-speed crop breeding via genome editing technology

Prof. Hiroshi Ezura

Professor/Director
Tsukuba Plant Innovation Research Center
University of Tsukuba

In Japanese

Genome editing for phytochemical genomics

Prof. Kazuki Saito

Professor,Chiba University / Deputy Director, RIKEN

In Japanese

Big data of genomic and crop information will realize efficient data-driven breeding

Dr. Hiroyoshi Iwata

Associate Professor
Laboratory of Biometry and Bioinformatics
Graduate School of Agricultural and Life Sciences, The University of Tokyo

In Japanese

Panel discussion


Oct.12(Fri.)      14  :  15  ~  15  :  15

F201
【S-17】 IHI Plant Engineering Corporation
Pre-Registration required

User collaboration in scale up of culture tank

Coordinator


MITSUBISHI GAS CHEMICAL COMPANY, INC.

In Japanese

IHI Plant Engineering Corporation

In Japanese